SHH and ependymoma: For all ependymomas and medulloblastomas where methylation was employed, profiling was able to subclassify tumors into either PFA or PFB subtypes of ependymoma (WHO recognized entities as of 2021) and was able to subclassify medulloblastomas into either WNT-activated, SHH-activated, or non-WNT/non-SHH-activated subtypes (as mandated by the WHO since 2016).